Answer:
Metaphase ⇒ Chromosomes line up in the middle of the cell
Prophase ⇒ DNA condenses to form chromosomes
Anaphase ⇒ Each chromosome separates and moves to opposite ends of the cell
Telophase ⇒ Nuclear membranes form around each set of chromosomes
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
Answer:
C. The enzyme with mutation 1 has decreased affinity for pyridoxal phosphate, whereas the enzyme with mutation 2 has lost the ability to bind to the substrates.
Explanation:
A coenzyme is an organic cofactor that binds with an enzyme in order to initiate or aid the function of the enzyme. A coenzyme binds to the active site of the enzyme (where the reaction occurs), thereby triggering its activation by modifying protein structure during the reaction. Some examples of coenzymes include Coenzyme A and Adenosine triphosphate (ATP). Pyridoxal phosphate is a coenzyme (it is the active form of vitamin B6) that is required for the function of cystathionase. Moreover, cystathionase is an enzyme that enables cells the synthesis of cysteine from methionine (transsulfuration pathway). The binding of pyridoxal phosphate to the enzyme increases the binding affinity of the enzyme for the substrate, thereby influencing its activity. In this case, it is expected that mutation 1 reduces the binding affinity of the enzyme to the cofactor, and thereby the cofactor is required at a higher concentration to restore normal enzyme activity.
You need to know 1) How much kinetic energy it absorbed before it broke.
2) What materials are able to scratch it.
3) Its mass.
